New-generation recombinant factor concentrates: bridge to gene therapy
M.V. Ragni,
M.V. Ragni
University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA
Search for more papers by this authorM.V. Ragni,
M.V. Ragni
University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA
Search for more papers by this author
Prof. M.V. Ragni
University of Pittsburgh Medical Center, Hemophilia Center of Western Pennsylvania, 3636 Boulevard of the Allies, Pittsburgh, PA, 15213–4306, USA.Tel.: 412 209 7288; Fax: 412 209 7281;e-mail: [email protected]
Abstract
Despite our best efforts to deceive the immune system, outwit pathogens, and improve upon the design of nature, there continues to be a need to improve the margin of safety of treatment for those with bleeding disorders. The current approach includes: (1) recombinant factor concentrates free of added proteins; (2) ‘designer’ factor molecules that enhance function and reduce immunogenicity; and (3) modulation of the immune system to suppress immune response in those who develop inhibitors. The hope is that through advances in our understanding of the coagulation and immune systems, treatment of haemophilia in the new millennium will be safer and less immunogenic. Currently available recombinant clotting factor concentrates include those produced: (1) with pasteurized human serum albumin in the cell culture medium as a stabilizer; (2) with bovine serum proteins in the cell culture medium; and (3) free of plasma derivatives. To the extent that current recombinant clotting factor concentrates contain even trace amounts of human or animal protein, there is continuing potential for transmission of nonenveloped viruses, including hepatitis A and parvovirus, and the theoretical potential for transmission of relatively unknown agents, such as prions (Creutzfeldt–Jakob disease or its variant). Second-generation recombinant factor concentrates that do not use human albumin as a stabilizer are currently in clinical trials, and third-generation recombinant factor concentrates currently in development take advantage of new strategies to achieve a ‘protein-free’ cell culture, purification, and final formulation. It is likely that improvement in safety and reduction in immunogenicity will require modification not only of antigenic structure but also of the immune response to coagulation proteins.
Bibliography
- 1 Rosner F. Hemophilia in the Talmud and Rabbinic writings. Ann Intern Med 1969; 70: 833–7.
- 2 McKusick VA. The royal hemophilia. Sci Am 1965; 213: 88–95.
- 3 Pool JG & Shannon AE. Production of high potency concentrates of antihemophilic globulin in a closed bag system. New Engl J Med 1965; 273: 1443–7.
- 4 Kekwick RA & Wolf P. A concentrate of human antihaemophilic factor – its use in six cases of haemophilia. Lancet 1957; i: 647–50.
- 5 Kasper CK & Kipnis SA. Hepatitis and clotting-factor concentrates. JAMA 1972; 221: 510 (letter).
- 6 Ragni MV, Ndimbie OK, Rice EO, Bontempo FA & Nedjar S. Presence of antibody to hepatitis C virus (HCV) in hemophilic men with HCV ‘seroreversion’. Blood 1993; 82: 1010–5.
- 7 Ragni MV, Winkelstein A, Kingsley LA, Spero JA & Lewis JH. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with haemophilia A and B. Blood 1987; 70: 786–90.
- 8 Mannucci PM, Gdovin S & Gringeri A et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994; 120: 1–7.
- 9 Azzi A, Ciappi SD, Zakvrewska KM, Morfini M, Mariani G & Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally-attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228–30.
- 10 Creange A, Gray F, Cesaro P & Degos JD. Pooled plasma derivatives and Creutzfeld-Jakob disease. Lancet 1996; 347: 482.
- 11 Revised recommendation regarding the use of recombinant clotting factor concentrate therapies. MASAC Recommendation #89. Hemaware 1999; 4: 24–7.
- 12 Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC & Kaufman RJ. A large region (∼95 kDA) of human factor VIII is dispensible for in vitro activity. Proc Natl Acad Sci USA 1986; 83: 5939–42.
- 13 Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78: 256–60.
- 14 Kessler CM, Spira J & Fraunhofer A. Safety and efficacy of an albumin-free formulated, B-domain deleted recombinant factor VIII (BBD rFVIII, rVIII SQ) in previously treated patients (PTPs): a four-year update. Thromb Haemost 1999; 472 (Suppl): 1493.
- 15 Lusher JM, Spira J & Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated, B-domain deleted factor VIII (BBD rFVIII, rVIII SQ) in previously untreated severe hemophilia A patients. Thromb Haemost 1999; 472 (Suppl): 1472.
- 16 Package insert, NovoSevenCoagulation Factor VIIa, (Recombinant). Novo Nordisk Pharmaceuticals, Inc, Princeton NJ1999.
- 17 Lusher JM, Roberts HR & Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle, and mucocutaneous hemorrhages in persons with hemophilia A and B, with and without inhibitors. Haemophilia 1998; 4: 790–8.
- 18 Absire T, Brackmann MM & Scharrer I et al. Sucrose-formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: results of a multicenter, international, clinical investigation. Thromb Haemost 2000; 83: 811–16.
- 19 Peerlink K & Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775–6.
- 20 Package insert, BenefixCoagulation Factor IX(Recombinant). Genetics Institute, Cambridge, MA1997.
- 21 White G, Shapiro A & Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35(Suppl. 2) 33–8.
- 22 Shapiro A, Abshire T & Gill J et al. Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPs) with severe or moderately severe hemophilia B. Thromb Haemost 1999; 473 (Suppl.): 1495.
- 23 Ewenstein BM, Takemoto C & Warrier I et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115–6.
- 24 Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sang 1996; 70(Suppl. 1): 9–14.
- 25 Lusher JM, Arkin S, Abildgaard CF & Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. N Engl J Med 1993; 328: 453–9.
- 26 Lipton RA. The economics of factor VIII inhibitor treatment. Semin Hematol 1994; 31: 37–8.
- 27 Eibl MM, Ahmad R, Wolf HM, Linnau Y, Gotz E & Mannhalter JW. A component of factor VIII preparations which can be separated from factor VIII activity down-modulates human monocyte functions. Blood 1987; 69: 1153–60.
- 28 Pasi KJ, Evans JA, Wadhwa M, Thorpe R & Hill FG. Association of changes in monocyte antigen presentation and cytokine production in haemophilic boys with treatment and blood-borne virus infection. Br J Haematol 1995; 91: 191–6.
- 29 Kaplan J, Sarnaik J, Gitlin J & Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 1984; 64: 308–10.
- 30 Weimer R, Zipperle S, Daniel V & Opelz G. In vitro cytokine treatment of B cell defects in HIV-infected haemophilia patients. Vox Sang 1995; 69: 27–37.
- 31 Schogl D, Zimmerman K, Turecek PL, Schwarz HP, Eibl MM & Mannhalter JW. Effect of high- versus intermediate-purity blood coagulation factor concentrates on HIV-1 replication. Vox Sang 1996; 70: 195–7.
- 32 Ragni MV, Ruben RL, Winkelstein A, Spero JA, Bontempo FA & Lewis JH. Antibody response to immunization in patients with haemophilia with and without evidence of HTLV-III infection. J Lab Clin Med 1987; 109: 545–9.
- 33 Ragni MV, Lusher J, Koerper M, Manco-Johnson M & Krause D. Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with hemophilia. Haemophilia 2000; 6: 98–103.
- 34 Thorpe R, Dilger P, Dawson NJ & Barrocliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 1989; 71: 387–91.
- 35 Ragni MV, Amato DA & Lofaro ML et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and non-hemophilic subjects with asymptomatic HIV-1 infection. Blood 1995; 85: 2337–46.
- 36 Wadhha M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T & Thorpe R. Identification of transforming growth factor-β as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood 1994; 84: 2021–30.
- 37 Ewenstein B, Ross F & Liu CL et al. Hemophilia treatment in Massachusetts: trends of care and economic implications. Hemaware 1999; 4: 12 (Abstract).
- 38 Kaufman RJ & Pipe SW. Can we improve on nature? ‘Super molecules’ of factor. Haemophilia 1998; 4: 370–9.
- 39 Hoyer LW Hemophilia A. New Engl J Med 1994; 330: 38–47.
- 40 Scandella D, Mondor W & Klinge J. The natural history of the immune response to exogenous factor VIII in severe hemophilia A. Haemophilia 1998; 4: 546–51.
- 41 Pipe SW & Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851–6.
- 42 Scandella D, Mattingly M, De Graaf S & Fulcher CA. Localization of epitopes of human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618–26.
- 43 Fulcher CA, De Graaf Mahoney S, Roberts JR, Kasper CK & Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728–32.
- 44 Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K & Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature 1999; 402: 439–41.
- 45 Lubin IM, Healey JF, Barrow RT, Scandella D & Lollar P. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem 1997; 272: 30191–5.
- 46 Lollar P & Parker CG. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 265: 12481–6.
- 47 Yamanaka K, Amano K, Nagaizumi K, Arai M, Kaufman RJ & Fukutake K. Folding of the C-domain of factor VIII is essential for its secretion. Thromb Haemost 1999; 91(Suppl.): 275A.
- 48 Amano K, Michnick DA, Moussalli M & Kaufman RJ. Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC) -mediated inactivation: implications for the APC resistance test. Thromb Haemost 1998; 79: 557–63.
- 49 Larsen CP, Elwood ET & Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434–8.
- 50 Fields PA, Arruda VR, Herzog RW, Couto LB, Pasi KJ & High KA. Immunomodulation suppresses inhibitor formation in a muscle-directed gene therapy in hemophilia B mice with a large F.IX gene deletion. Thromb Haemost 1999; 409(Suppl.): 1298 (Abstract).
- 51 Kirk AD, Harlan DM & Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 87–94.
- 52 Croix DA, Ahearn JM & Rosengard AM et al. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J Exp Med 1996; 183: 1857–64.
Citing Literature
